Preventive Effects of Piperlonguminine on Alcoholic Fatty Liver Disease in Mice

Ri-ge-tu ZHAO,Chao-lu-men BAI,Ge-ri-le-tu BO,Ri-su NA,Xiao LING
DOI: https://doi.org/10.7506/spkx1002-6630-201413045
2014-01-01
Abstract:This study aimed to investigate the preventive and therapeutic effects of piperlonguminine(GBN) on alcoholic fatty liver disease(AFLD) in mice. Adult male Kunming mice were randomly divided into four groups: normal control, model, GBN low dose and high dose groups. The mice in normal control group were fed with a normal diet, and those in the other groups were fed with high-fat diet, and, at the same time, administered with alcohol daily at a level of 0.8 mL/30 g bw. The mice in GBN low and high dose groups were intragastrically administered with 0.8 mL/30 g bw of GBN at doses of 10 and 40 mg/(kg·d), respectively, and the normal control and model groups were given equal volume of distilled water, continuously for 6 weeks. After 12 h of fasting following the last administration, all the mice were sacrificed for the measurement of liver index, aspartate transaminase(AST), alanine transaminase(ALT), total cholesterol(TC) and triglyceride(TG) levels in serum and the pathological histological observation of liver tissue. Compared with the model group, the low and high dose groups significantly decreased liver index to(4.42 ± 0.50)% and(4.53 ± 0.44)%, respectively. Also, the levels of AST, ALT, TC and TG in serum were significantly decreased(P 0.01). And pathological histology showed that GBN obviously improved hepatocyte fatty degeneration of alcoholic fatty liver in mice. In conclusion, GBN can effectively prevent the occurrence and development of alcoholic fatty liver.
What problem does this paper attempt to address?